<DOC>
	<DOCNO>NCT03094468</DOCNO>
	<brief_summary>The aim phase III study establish efficacy safety P-3058 ( terbinafine 10 % nail solution ) topically administer weekly patient onychomycosis comparison Vehicle double-blind fashion . The overall treatment period 48 week .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety P-3058 Nail Solution Treatment Onychomycosis</brief_title>
	<detailed_description>The study consist screen phase , treatment phase 48 week 12-week follow-up . Patients affect mild to-moderate distal lateral subungual onychomycosis ( DLSO ) target great toenail include study . Clinical well mycology assessment perform throughout whole study . Safety monitor record adverse event evaluate local tolerability .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>Written inform consent start study related procedure . Patients age 12 old race . Males female . Outpatients . Clinically diagnose mildtomoderate distal lateral subungual onychomycosis ( DLSO ) least one great toenail ( `` target nail '' ) Screening visit ( V1 ) . Patients onychomycosis involve ≥ 20 % ≤ 50 % area target great toenail . Patients positive KOH examination . Patients positive culture dermatophyte ( ) . Evidence target great toenail growth report patient define least monthly nail clipping . Woman pregnant , nursing infant , plan pregnancy study period . Patients history allergic reaction terbinafine excipients . Use investigational drug/device participation previous clinical trial within four week prior Screening visit ( V1 ) . Patients use nail polish nail cosmetic product concern nail least 24 hour prior Screening visit ( V1 ) end study . Use systemic antifungal drug 24 week prior Screening visit ( V1 ) nonresponsive systemic antifungal therapy onychomycosis . Nail application topical antifungal drug device 4 week prior Screening visit ( V1 ) . Presence nail infection dermatophyte . Presence onychodystrophy could interfere clinical assessment . Presence `` yellow spike '' target nail . Presence dermatophytoma target nail . Presence nail thickness exceed 2 mm . Patients proximal subungual involvement ( marker immunosuppressed patient ) . Patients severe plantar moccasin tinea pedis ( defined blistering , pustules inability ambulate ) . Patients nail abnormality due condition like psoriasis , lichen planus , immune dysfunction , collagenvascular disease , peripheral vascular disease . Patients life expectancy le 2 year . Chemotherapy , immunosuppressive therapy 12 week prior Screening visit ( V1 ) . Systemic corticosteroid , antimetabolites immunestimulants therapy 4 week prior Screening visit ( V1 ) . HIV infection immunodeficiency . Alcohol substance abuse . Patients/parents ( legal guardian ) unable understand procedure purpose study . Any condition , opinion Investigator , would prevent subject effectively participate study , place subject risk effect assessment efficacy safety study medication .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>terbinafine nail solution</keyword>
	<keyword>nail fungal infection</keyword>
	<keyword>topical antifungal drug</keyword>
</DOC>